Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead to a state of total dependence.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
Do the benefits of approving a drug before confirming it works outweigh the potential costs?
monkeybusinessimages/iStock via Getty Images Plus
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
A COVID-19 vaccine is administered at a clinic at Olympic Stadium in Montréal on March 1, 2021, marking the beginning of mass vaccination in the Province of Québec based on age.
THE CANADIAN PRESS/Paul Chiasson
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
By - https://www.nlm.nih.gov/hmd/emotions/self.html , , Public Domain, https://commons.wikimedia.org/w/index.php?curid=1684469.
Elaine and Arthur Shapiro/Wikimedia Commons
A whistle-stop tour of the history of placebos.
We still don’t know if current vaccines prevent people from transmitting the virus to others. Here’s why that matters in 2021.
The reason the vaccine appears to have worked better in participants who initially received only half a dose is still somewhat of a mystery.
Vaccines are being touted as taking seven to ten years to develop. But you shouldn’t be worried that COVID vaccines only took less than a year.
A woman walks by graffiti reading ‘No vaccine, No tracking, No COVID’, in Montréal on Aug. 16, 2020.
THE CANADIAN PRESS/Graham Hughes
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
Any COVID-19 vaccine is likely to be given first to higher risk groups before it is given to children. But we still need vaccines that are safe and effective for them too.
Pregnant women are routinely excluded from clinical trials for drugs and vaccines.
Pregnant women are at increased risk for serious COVID-19 complications and should be a high-priority group for vaccination. Excluding them from vaccine trials puts them and their offspring at risk.
There are many scientific and ethical challenges ahead. But these types of trials have helped in the development of vaccines against a few diseases. Could they do the same for COVID-19?
Australia’s contribution to the global COVAX initiative helps secure future vaccines. Here’s the full field of candidates.
A lab technician holds a vial of a COVID-19 vaccine candidate during testing at the Chula Vaccine Research Center, run by Chulalongkorn University in Bangkok, Thailand on May 25, 2020.
(AP Photo/Sakchai Lalit)
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
Stoppages of clinical trials are a normal part of the testing process, and show that patient safety is being taken seriously.
A researcher working on the University of Oxford/AstraZeneca vaccine in Buenos Aires.
The COVID-19 vaccine is in the final stages of testing – meaning we should know whether it’s effective before the end of the year.